Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21722836 | 0.86 | SIGMAR1 (0.60) | SIGMAR1FAAHCYP2D6 | |
| SCHEMBL22589573 | 0.85 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AHTTGRIN2B | |
| SCHEMBL9760056 | 0.84 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9AHTTGRIN2B | |
| SCHEMBL13450952 | 0.84 | GRIN2B (0.71) | SMN1; SMN2NPC1RAB9AHTTGRIN2B | |
| SCHEMBL7819807 | 0.83 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL3557188 | 0.83 | GAA (0.61) | SMN1; SMN2NPC1RAB9AHTTGRIN2B | |
| SCHEMBL22126801 | 0.83 | SIGMAR1 (0.68) | SIGMAR1SMN1; SMN2HTTFAAHACHE | |
| SCHEMBL6593704 | 0.83 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AHTTGRIN2B | |
| SCHEMBL13168269 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AHTTGRIN2B | |
| SCHEMBL15747761 | 0.82 | SMN1; SMN2 (0.58) | SIGMAR1SMN1; SMN2NPC1RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790751-B2 | Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790751-B2 | Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790751-B2 | Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-09-07 | — | — | US | disclosed |
| CN-101291913-A | Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH CORP (US) | 2008-10-22 | — | — | CN | disclosed |
| EP-1915348-A1 | AZINYL-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth a Corporation of the State of Delaware (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007032833-A1 | AZINYL-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007032833-A1 | AZINYL-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-03-22 | — | — | WO | disclosed |
| US-20070054896-A1 | Serotonin (5-HT6) receptor ligands such as 3-(1-naphthylsulfonyl)-5-(piperidin-4-yloxy)-1H-indazole, used for the treatment nervous sytem disorders such as attention deficit disorder, anxiety, epilepsy, depression, schizophrenia, obsessive compulsive, sleep, eating and neurodegenerative disorders | WYETH (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054896-A1 | Serotonin (5-HT6) receptor ligands such as 3-(1-naphthylsulfonyl)-5-(piperidin-4-yloxy)-1H-indazole, used for the treatment nervous sytem disorders such as attention deficit disorder, anxiety, epilepsy, depression, schizophrenia, obsessive compulsive, sleep, eating and neurodegenerative disorders | WYETH (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054896-A1 | Serotonin (5-HT6) receptor ligands such as 3-(1-naphthylsulfonyl)-5-(piperidin-4-yloxy)-1H-indazole, used for the treatment nervous sytem disorders such as attention deficit disorder, anxiety, epilepsy, depression, schizophrenia, obsessive compulsive, sleep, eating and neurodegenerative disorders | WYETH (US) | 2007-03-08 | — | — | US | disclosed |
| US-5057528-A | AMINO-PYRIDINE COMPOUNDS USEFUL AS ANTI-ARRHYTHMIC AGENTS | PFIZER INC. (US) | 1991-10-15 | — | — | US | disclosed |
| US-4968704-A | PROLONG DURATION OF ACTION POTENTIAL IN CARDIAC MUSCLE AND CONDUCTING TISSUE | PFIZER INC. (US) | 1990-11-06 | — | — | US | disclosed |
| EP-0359389-A1 | Antiarrhythmic agents | Pfizer Limited (GB) | 1990-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054896-A1 | Serotonin (5-HT6) receptor ligands such as 3-(1-naphthylsulfonyl)-5-(piperidin-4-yloxy)-1H-indazole, used for the treatment nervous sytem disorders such as attention deficit disorder, anxiety, epilepsy, depression, schizophrenia, obsessive compulsive, sleep, eating and neurodegenerative disorders | HTR6, HTR1A, HTR3B | SIGMAR1 171/4885SMN1; SMN2 873/4885NPC1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.